# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of...
Cash and cash equivalents were $119.2 million as of March 31, 2024.
PH15 nasal spray demonstrates statistically significant efficacy versus placebo and caffeine in a placebo-controlled Phase 2A p...
Key study underway in registration-directed PALISADE Phase 3 program for fasedienol in social anxiety disorderSocial anxiety di...
VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of...
Companies Reporting Before The Bell • LCI Indus (NYSE:LCII) is likely to report quarterly earnings at $0.18 per share on reven...